Education
About Us
Working with TipRanks
Follow Us
Champions Oncology (CSBR)
:CSBR
Top Page
Champions Oncology
(NASDAQ:CSBR)
49Neutral
Champions Oncology (CSBR) vs. S&P 500 (SPY)
Market Cap
$81.86M
Dividend YieldN/A
Average Volume (3M)37.45K
Price to Earnings (P/E)13.1
Beta (1Y)0.55
Revenue Growth19.03%
EPS GrowthN/A
CountryUS
Employees210
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)0.36
Shares Outstanding13,826,904
10 Day Avg. Volume30,186
30 Day Avg. Volume37,450
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)15.58
Price to Sales (P/S)0.00
P/FCF Ratio-65.01
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue0.42
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda24.39
Forecast
1Y Price Target
$12.00Price Target Upside88.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Champions Oncology Business Overview & Revenue Model
Company DescriptionChampions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
How the Company Makes MoneyChampions Oncology generates revenue primarily through its personalized oncology solutions and technology platforms, which it offers to pharmaceutical companies, academic institutions, and other research organizations engaged in cancer drug development. The company's main revenue streams include the sale of its PDX models, which are used for preclinical testing and drug discovery, as well as its drug testing services that provide critical data to optimize drug development processes. Additionally, Champions Oncology engages in strategic partnerships and collaborations with leading pharmaceutical firms to expand its service offerings and enhance its market reach, further contributing to its financial performance.
Champions Oncology Financial Statement Overview
Summary
Champions Oncology's financial statements depict a company facing significant challenges in revenue stability and cash management, despite some improvements in equity and net income. The high leverage and inconsistent profit margins reflect potential risks, while cash flow issues underscore liquidity concerns. Overall, the company is in a transitional phase, showing both vulnerabilities and some recovery indicators.Income Statement
The company exhibits a volatile income statement with a negative gross profit margin in TTM, indicating more costs than revenue. Despite a positive net income in TTM, the revenue growth rate is negative, showing declining sales over time. Margins are inconsistent, with significant fluctuations in EBIT and EBITDA margins. The overall income statement suggests instability in revenue generation and cost management.40
Negative
Balance Sheet
The balance sheet reveals a concerning debt-to-equity ratio, indicating high leverage. However, the TTM data shows improved stockholders' equity, suggesting a recovery trend. ROE is positive in TTM, reflecting recent profitability. The equity ratio remains low, indicating potential financial risk due to dependence on liabilities. The balance sheet points to a moderate risk profile with some signs of recovery.45
Neutral
Cash Flow
Cash flow analysis shows negative free cash flow growth in TTM, reflecting cash management challenges. The operating cash flow to net income ratio is negative, indicating cash outflows even with positive net income. This trend suggests problems in converting earnings into cash. The cash flow statement highlights liquidity challenges and inefficiencies in cash operations.35
Negative
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 58.59M | 50.16M | 53.87M | 49.11M | 41.04M | 32.12M | Gross Profit |
| 30.58M | 20.75M | 24.34M | 25.48M | 19.57M | 15.24M | EBIT |
| 6.72M | -7.36M | -4.45M | 607.00K | 338.00K | -1.47M | EBITDA |
| 8.45M | -5.05M | -2.07M | 2.23M | 366.00K | -735.00K | Net Income Common Stockholders |
| 6.43M | -7.28M | -5.33M | 548.00K | 362.00K | -1.98M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.20M | 2.62M | 10.12M | 9.01M | 4.69M | 8.34M | Total Assets |
| 30.63M | 26.13M | 34.31M | 35.38M | 27.59M | 20.75M | Total Debt |
| 6.44M | 7.43M | 8.60M | 9.47M | 9.60M | 3.80M | Net Debt |
| 3.23M | 4.81M | -1.52M | 459.00K | 4.91M | -4.54M | Total Liabilities |
| 25.16M | 28.04M | 29.68M | 26.28M | 20.16M | 15.43M | Stockholders Equity |
| 5.47M | -1.90M | 4.64M | 9.10M | 7.43M | 5.32M |
| Cash Flow | Free Cash Flow | ||||
| -1.32M | -6.97M | 1.08M | 4.11M | -4.96M | 685.00K | Operating Cash Flow |
| -1.30M | -6.14M | 3.96M | 6.50M | -1.68M | 2.90M | Investing Cash Flow |
| -25.00K | -836.00K | -2.87M | -2.38M | -3.17M | -2.22M | Financing Cash Flow |
| 57.00K | -527.00K | 11.00K | 207.00K | 1.20M | 4.42M |
Champions Oncology Technical Analysis
Negative
6.35
Price Trends
7.94
Negative
9.03
Negative
6.83
Negative
Market Momentum
-0.55
Negative
36.74
Neutral
53.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 6.35 is below the 20-day moving average (MA) of 6.62, below the 50-day MA of 7.94, and below the 200-day MA of 6.83, indicating a bearish trend. The MACD of -0.55 indicates Negative momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 53.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.
Champions Oncology Risk Analysis
Champions Oncology disclosed 30 risk factors in its most recent earnings report. Champions Oncology reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Champions Oncology Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $121.86M | ― | -24.73% | ― | -1.02% | -8.59% | |
52 Neutral | $5.19B | 3.04 | -44.64% | 2.82% | 16.45% | -0.53% | |
50 Neutral | $205.09M | ― | -91.44% | ― | -2.04% | -478.87% | |
49 Neutral | $81.86M | 13.15 | 376.84% | ― | 19.03% | ― | |
46 Neutral | $89.94M | ― | -59.45% | ― | ― | 48.92% | |
41 Neutral | $109.35M | ― | -45.55% | ― | 98.56% | 37.97% | |
30 Underperform | $93.42M | ― | -744.59% | ― | ― | 27.65% |
* Healthcare Sector Average
Performance Comparison
CSBR
Champions Oncology
5.92
1.16
24.37%
TNXP
Tonix Pharma
26.60
-581.40
-95.63%
ZNTL
Zentalis Pharmaceuticals
1.25
-10.54
-89.40%
CCCC
C4 Therapeutics
1.54
-4.08
-72.60%
SEER
Seer
2.07
-0.01
-0.48%
ELTX
Elicio Therapeutics
5.84
-4.02
-40.77%
Champions Oncology Earnings Call Summary
Earnings Call Date:Mar 11, 2025
(Q3-2025)
| % Change Since: -28.65%|
Next Earnings Date:Jul 17, 2025
Earnings Call Sentiment Positive
The earnings call reflected significant positive developments such as record-breaking revenue, successful data licensing, and improved financial metrics. However, challenges in the biotech sector and uncertainties regarding future data revenue contributions were highlighted. Despite the challenges, the company is optimistic about long-term growth.Q3-2025 Updates
Positive Updates
Record-Breaking Revenue and Growth
Champions Oncology had a record-breaking quarter with total revenue surpassing $17 million and adjusted EBITDA hitting a record high. Research service revenue was $12.5 million, an increase from $12 million in the same period last year. The company reported adjusted EBITDA of $5.2 million compared to an adjusted loss of $1.7 million in the prior year.
Successful Data Licensing Agreement
Champions Oncology successfully completed its first data licensing deal, marking the initial validation of its strategic vision to create a transformative data business. Data revenue contribution was $4.5 million, showcasing early traction of the new platform.
Improved Financial Metrics
On a GAAP basis, income from operations was $4.5 million compared to a loss of $2.6 million in the prior year. Total gross margin improved to 53% compared to 40% in the same period last year. Research service margins also improved to 48% compared to 35% in the same period last year.
Strong Cash Position
Champions Oncology ended the quarter with $3.2 million of cash on the balance sheet and no debt. Cash generated by operating activities was $900,000.
Negative Updates
Tight Biotech Sector Environment
Despite some improvement, the environment remains tight with a challenging funding environment in the biotech sector. The company is cautious about performance volatility due to uncertainties in the sector.
Uncertain Future Data Revenue Contribution
While the initial data deal is promising, it remains premature to forecast the number of future deals, their average size, or the frequency with which they will occur, making the future data revenue contribution uncertain.
Potential Short-term Volatility in Research Service Revenue
There is anticipation of short-term volatility in research service revenue, with some expected balance related in revenue and cost of sales.
Company Guidance
During the Champions Oncology Third Quarter Fiscal Year 2025 earnings call, CEO Ronnie Morris highlighted the company's record revenue of $17 million, driven by the closure of their first data deal. The core services business, anchored by their industry-leading PDX bank, continues to thrive. Morris noted a cautiously optimistic outlook for the biotech sector, despite a challenging environment. The demand for Champions' multiomic data set has increased, especially with the rise of AI, and the company is exploring ways to maximize its value. CFO David Miller reported that Q3 revenue reached $17 million, with research service revenue at $12.5 million and data revenue at $4.5 million. The gross margin improved to 61%, thanks to high-margin data revenue. Operating expenses decreased, contributing to a record adjusted EBITDA of $5.2 million. Despite short-term volatility, the company reaffirmed its full-year revenue growth guidance of 10% to 15%, focusing on expanding its data business and enhancing profitability.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.